why Recursion Pharmaceuticals Inc [RXRX] is a Good Choice for Investors After New Price Target of $15.57

Recursion Pharmaceuticals Inc [NASDAQ: RXRX] slipped around -0.33 points on Monday, while shares priced at $6.53 at the close of the session, down -4.81%. The company report on November 9, 2023 at 9:41 AM that Bayer and Recursion Focus Research Collaboration on Oncology.

Digitally enabled drug discovery for oncology has the potential to accelerate the delivery of new cancer therapies to patients. Drug discovery research collaboration may initiate up to seven oncology programs and further strengthens Bayer’s early pipeline in precision oncology. Recursion is eligible to receive up to $1.5 billion in potential development and commercial milestone payments plus royalties.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Recursion Pharmaceuticals Inc stock is now -15.30% down from its year-to-date (YTD) trading value. RXRX Stock saw the intraday high of $6.8095 and lowest of $6.50 per share. The company’s 52-week high price is 16.75, which means current price is +43.83% above from all time high which was touched on 07/19/23.

Compared to the average trading volume of 3.66M shares, RXRX reached a trading volume of 6333839 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Recursion Pharmaceuticals Inc [RXRX]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RXRX shares is $15.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RXRX stock is a recommendation set at 2.14. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Recursion Pharmaceuticals Inc shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on May 22, 2023.

The Average True Range (ATR) for Recursion Pharmaceuticals Inc is set at 0.51, with the Price to Sales ratio for RXRX stock in the period of the last 12 months amounting to 29.77. The Price to Book ratio for the last quarter was 3.21, with the Price to Cash per share for the same quarter was set at 1.80.

How has RXRX stock performed recently?

Recursion Pharmaceuticals Inc [RXRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -7.38. With this latest performance, RXRX shares gained by 17.66% in over the last four-week period, additionally sinking by -26.88% over the last 6 months – not to mention a drop of -29.33% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RXRX stock in for the last two-week period is set at 51.56, with the RSI for the last a single of trading hit 52.38, and the three-weeks RSI is set at 49.64 for Recursion Pharmaceuticals Inc [RXRX]. The present Moving Average for the last 50 days of trading for this stock 6.60, while it was recorded at 6.71 for the last single week of trading, and 7.89 for the last 200 days.

Recursion Pharmaceuticals Inc [RXRX]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Recursion Pharmaceuticals Inc [RXRX] shares currently have an operating margin of -616.74 and a Gross Margin at -22.11. Recursion Pharmaceuticals Inc’s Net Margin is presently recorded at -601.05.

Return on Total Capital for RXRX is now -45.04, given the latest momentum, and Return on Invested Capital for the company is -44.20. Return on Equity for this stock declined to -46.56, with Return on Assets sitting at -36.52. When it comes to the capital structure of this company, Recursion Pharmaceuticals Inc [RXRX] has a Total Debt to Total Equity ratio set at 10.50. Additionally, RXRX Total Debt to Total Capital is recorded at 9.50, with Total Debt to Total Assets ending up at 7.27. Long-Term Debt to Equity for the company is recorded at 9.25, with the Long-Term Debt to Total Capital now at 8.37.

Receivables Turnover for the company is 6.73 with a Total Asset Turnover recorded at a value of 0.06.Recursion Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.28 and a Current Ratio set at 4.28.

Earnings analysis for Recursion Pharmaceuticals Inc [RXRX]

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RXRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Recursion Pharmaceuticals Inc go to 12.00%.

Insider trade positions for Recursion Pharmaceuticals Inc [RXRX]

The top three institutional holders of RXRX stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in RXRX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in RXRX stock with ownership which is approximately 5.7994%.